摘要
Diabetic dyslipidemia is a cluster of lipoprotein abnormalities characterized by increased triglyceride level, decreased high-density lipoprotein-cholesterol levels and increase in small dense low-density lipoprotein(LDL) particles. It is extremely common in type 2 diabetes(T2DM) affecting around 70 % of patients.Diabetic is a significant risk factor for atherosclerotic cardiovascular disease(ASCVD) which is the most common cause of death in the United States and LDL-cholesterol is the number 1 predictor of ASCVD events in T2DM. The purpose of this review is to discuss the pathophysiology and treatment of diabetic dyslipidemia. In this review, we have discussed both nonpharmacological and pharmacological treatment modalities including major treatment trials which have impacted the cardiovascular outcomes in patients with diabetes. Statin therapy is the mainstay of treatment to reduce ASCVD by decreasing LDL-C by 30%-49% or at least 50% depending on risk level. Attractive adjunctive therapies include Ezetimibe which is more cost effective and PCSK9 inhibitors which display potent LDL-cholesterol lowering and ASCVD event reduction. For severe hypertriglyceridemia, to avert the risk of pancreatitis, both fish oil and fenofibrate in concert with diet is the best strategy.
Diabetic dyslipidemia is a cluster of lipoprotein abnormalities characterized by increased triglyceride level, decreased high-density lipoprotein-cholesterol levels and increase in small dense low-density lipoprotein(LDL) particles. It is extremely common in type 2 diabetes(T2DM) affecting around 70 % of patients.Diabetic is a significant risk factor for atherosclerotic cardiovascular disease(ASCVD) which is the most common cause of death in the United States and LDL-cholesterol is the number 1 predictor of ASCVD events in T2DM. The purpose of this review is to discuss the pathophysiology and treatment of diabetic dyslipidemia. In this review, we have discussed both nonpharmacological and pharmacological treatment modalities including major treatment trials which have impacted the cardiovascular outcomes in patients with diabetes. Statin therapy is the mainstay of treatment to reduce ASCVD by decreasing LDL-C by 30%-49% or at least 50% depending on risk level. Attractive adjunctive therapies include Ezetimibe which is more cost effective and PCSK9 inhibitors which display potent LDL-cholesterol lowering and ASCVD event reduction. For severe hypertriglyceridemia, to avert the risk of pancreatitis, both fish oil and fenofibrate in concert with diet is the best strategy.
引文
1 Heron M.Deaths:Leading Causes for 2016.Natl Vital Stat Rep 2018;67:1-77[PMID:[[30248017]
2 Benjamin EJ,Virani SS,Callaway CW,Chamberlain AM,Chang AR,Cheng S,Chiuve SE,Cushman M,Delling FN,Deo R,de Ferranti SD,Ferguson JF,Fornage M,Gillespie C,Isasi CR,Jiménez MC,Jordan LC,Judd SE,Lackland D,Lichtman JH,Lisabeth L,Liu S,Longenecker CT,Lutsey PL,Mackey JS,Matchar DB,Matsushita K,Mussolino ME,Nasir K,O'Flaherty M,Palaniappan LP,Pandey A,Pandey DK,Reeves MJ,Ritchey MD,Rodriguez CJ,Roth GA,Rosamond WD,Sampson UKA,Satou GM,Shah SH,Spartano NL,Tirschwell DL,Tsao CW,Voeks JH,Willey JZ,Wilkins JT,Wu JH,Alger HM,Wong SS,Muntner P;American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee.Heart Disease and Stroke Statistics-2018 Update:AReport From the American Heart Association.Circulation 2018;137:e67-e492[PMID:[[29386200 DOI:10.1161/CIR.0000000000000558]
3 World Health Organization.Global report on diabetes.2016;Available from:http://www.who.int/iris/handle/10665/204871
4 Stratton IM,Adler AI,Neil HA,Matthews DR,Manley SE,Cull CA,Hadden D,Turner RC,Holman RR.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes(UKPDS 35):prospective observational study.BMJ 2000;321:405-412[PMID:[[10938048]
5 Jialal I,Bajaj M.Therapy and clinical trials:management of diabetic dyslipidemia.Curr Opin Lipidol2009;20:85-86[PMID:[[19106714 DOI:10.1097/MOL.0b013e32832210b0]
6 Mazzone T,Chait A,Plutzky J.Cardiovascular disease risk in type 2 diabetes mellitus:insights from mechanistic studies.Lancet 2008;371:1800-1809[PMID:[[18502305 DOI:10.1016/S0140-6736(08)60768-0]
7 Vergès B.Pathophysiology of diabetic dyslipidaemia:where are we?Diabetologia 2015;58:886-899[PMID:[[25725623 DOI:10.1007/s00125-015-3525-8]
8 Lorenzo C,Hartnett S,Hanley AJ,Rewers MJ,Wagenknecht LE,Karter AJ,Haffner SM.Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes:the insulin resistance atherosclerosis study.J Clin Endocrinol Metab 2013;98:1622-1630[PMID:[[23450048DOI:10.1210/jc.2012-3185]
9 Adiels M,Olofsson SO,Taskinen MR,Borén J.Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.Arterioscler Thromb Vasc Biol 2008;28:1225-1236[PMID:[[18565848 DOI:10.1161/ATVBAHA.107.160192]
10 Wu L,Parhofer KG.Diabetic dyslipidemia.Metabolism 2014;63:1469-1479[PMID:[[25242435 DOI:10.1016/j.metabol.2014.08.010]
11 Guérin M,Le Goff W,Lassel TS,Van Tol A,Steiner G,Chapman MJ.Atherogenic role of elevated CEtransfer from HDL to VLDL(1)and dense LDL in type 2 diabetes:impact of the degree of triglyceridemia.Arterioscler Thromb Vasc Biol 2001;21:282-288[PMID:[[11156866]
12 Hirany S,O'Byrne D,Devaraj S,Jialal I.Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease.Clin Chem 2000;46:667-672[PMID:[[10794749]
13 TG and HDL Working Group of the Exome Sequencing Project,National Heart,Lung,and Blood Institute.Crosby J,Peloso GM,Auer PL,Crosslin DR,Stitziel NO,Lange LA,Lu Y,Tang ZZ,Zhang H,Hindy G,Masca N,Stirrups K,Kanoni S,Do R,Jun G,Hu Y,Kang HM,Xue C,Goel A,Farrall M,Duga S,Merlini PA,Asselta R,Girelli D,Olivieri O,Martinelli N,Yin W,Reilly D,Speliotes E,Fox CS,Hveem K,Holmen OL,Nikpay M,Farlow DN,Assimes TL,Franceschini N,Robinson J,North KE,Martin LW,DePristo M,Gupta N,Escher SA,Jansson JH,Van Zuydam N,Palmer CN,Wareham N,Koch W,Meitinger T,Peters A,Lieb W,Erbel R,Konig IR,Kruppa J,Degenhardt F,Gottesman O,Bottinger EP,O'Donnell CJ,Psaty BM,Ballantyne CM,Abecasis G,Ordovas JM,Melander O,Watkins H,Orho-Melander M,Ardissino D,Loos RJ,McPherson R,Willer CJ,Erdmann J,Hall AS,Samani NJ,Deloukas P,Schunkert H,Wilson JG,Kooperberg C,Rich SS,Tracy RP,Lin DY,Altshuler D,Gabriel S,Nickerson DA,Jarvik GP,Cupples LA,Reiner AP,Boerwinkle E,Kathiresan S.Loss-of-function mutations in APOC3,triglycerides,and coronary disease.N Engl J Med 2014;371:22-31[PMID:[[24941081 DOI:10.1056/NEJMoa1307095]
14 Do R,Willer CJ,Schmidt EM,Sengupta S,Gao C,Peloso GM,Gustafsson S,Kanoni S,Ganna A,Chen J,Buchkovich ML,Mora S,Beckmann JS,Bragg-Gresham JL,Chang HY,Demirkan A,Den Hertog HM,Donnelly LA,Ehret GB,Esko T,Feitosa MF,Ferreira T,Fischer K,Fontanillas P,Fraser RM,Freitag DF,Gurdasani D,Heikkil?K,Hypp?nen E,Isaacs A,Jackson AU,Johansson A,Johnson T,Kaakinen M,Kettunen J,Kleber ME,Li X,Luan J,Lyytik?inen LP,Magnusson PK,Mangino M,Mihailov E,Montasser ME,Müller-Nurasyid M,Nolte IM,O'Connell JR,Palmer CD,Perola M,Petersen AK,Sanna S,Saxena R,Service SK,Shah S,Shungin D,Sidore C,Song C,Strawbridge RJ,Surakka I,Tanaka T,Teslovich TM,Thorleifsson G,Van den Herik EG,Voight BF,Volcik KA,Waite LL,Wong A,Wu Y,Zhang W,Absher D,Asiki G,Barroso I,Been LF,Bolton JL,Bonnycastle LL,Brambilla P,Burnett MS,Cesana G,Dimitriou M,Doney AS,D?ring A,Elliott P,Epstein SE,Eyjolfsson GI,Gigante B,Goodarzi MO,Grallert H,Gravito ML,Groves CJ,Hallmans G,Hartikainen AL,Hayward C,Hernandez D,Hicks AA,Holm H,Hung YJ,Illig T,Jones MR,Kaleebu P,Kastelein JJ,Khaw KT,Kim E,Klopp N,Komulainen P,Kumari M,Langenberg C,Lehtim?ki T,Lin SY,Lindstr?m J,Loos RJ,Mach F,McArdle WL,Meisinger C,Mitchell BD,Müller G,Nagaraja R,Narisu N,Nieminen TV,Nsubuga RN,Olafsson I,Ong KK,Palotie A,Papamarkou T,Pomilla C,Pouta A,Rader DJ,Reilly MP,Ridker PM,Rivadeneira F,Rudan I,Ruokonen A,Samani N,Scharnagl H,Seeley J,Silander K,Stan?ákováA,Stirrups K,Swift AJ,Tiret L,Uitterlinden AG,van Pelt LJ,Vedantam S,Wainwright N,Wijmenga C,Wild SH,Willemsen G,Wilsgaard T,Wilson JF,Young EH,Zhao JH,Adair LS,Arveiler D,Assimes TL,Bandinelli S,Bennett F,Bochud M,Boehm BO,Boomsma DI,Borecki IB,Bornstein SR,Bovet P,Burnier M,Campbell H,Chakravarti A,Chambers JC,Chen YD,Collins FS,Cooper RS,Danesh J,Dedoussis G,de Faire U,Feranil AB,Ferrières J,Ferrucci L,Freimer NB,Gieger C,Groop LC,Gudnason V,Gyllensten U,Hamsten A,Harris TB,Hingorani A,Hirschhorn JN,Hofman A,Hovingh GK,Hsiung CA,Humphries SE,Hunt SC,Hveem K,Iribarren C,J?rvelin MR,Jula A,K?h?nen M,Kaprio J,Kes?niemi A,Kivimaki M,Kooner JS,Koudstaal PJ,Krauss RM,Kuh D,Kuusisto J,Kyvik KO,Laakso M,Lakka TA,Lind L,Lindgren CM,Martin NG,M?rz W,McCarthy MI,McKenzie CA,Meneton P,Metspalu A,Moilanen L,Morris AD,Munroe PB,Nj?lstad I,Pedersen NL,Power C,Pramstaller PP,Price JF,Psaty BM,Quertermous T,Rauramaa R,Saleheen D,Salomaa V,Sanghera DK,Saramies J,Schwarz PE,Sheu WH,Shuldiner AR,Siegbahn A,Spector TD,Stefansson K,Strachan DP,Tayo BO,Tremoli E,Tuomilehto J,Uusitupa M,van Duijn CM,Vollenweider P,Wallentin L,Wareham NJ,Whitfield JB,Wolffenbuttel BH,Altshuler D,Ordovas JM,Boerwinkle E,Palmer CN,Thorsteinsdottir U,Chasman DI,Rotter JI,Franks PW,Ripatti S,Cupples LA,Sandhu MS,Rich SS,Boehnke M,Deloukas P,Mohlke KL,Ingelsson E,Abecasis GR,Daly MJ,Neale BM,Kathiresan S.Common variants associated with plasma triglycerides and risk for coronary artery disease.Nat Genet 2013;45:1345-4352[PMID:[[3773200]
15 Castelli WP,Garrison RJ,Wilson PW,Abbott RD,Kalousdian S,Kannel WB.Incidence of coronary heart disease and lipoprotein cholesterol levels.The Framingham Study.JAMA 1986;256:2835-2838[PMID:[[3773200]
16 AIM-HIGH Investigators;Boden WE,Probstfield JL,Anderson T,Chaitman BR,Desvignes-Nickens P,Koprowicz K,McBride R,Teo K,Weintraub W.Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.N Engl J Med 2011;365:2255-2267[PMID:[[22085343 DOI:10.1056/NEJMoa1107579]
17 Carmena R,Duriez P,Fruchart JC.Atherogenic lipoprotein particles in atherosclerosis.Circulation 2004;109:III2-III7[PMID:[[15198959]
18 Turner RC,Millns H,Neil HA,Stratton IM,Manley SE,Matthews DR,Holman RR.Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus:United Kingdom Prospective Diabetes Study(UKPDS:23).BMJ 1998;316:823-828[PMID:[[9549452 DOI:10.1136/bmj.316.7134.823]
19 Stone NJ,Robinson JG,Lichtenstein AH,Bairey Merz CN,Blum CB,Eckel RH,Goldberg AC,Gordon D,Levy D,Lloyd-Jones DM,McBride P,Schwartz JS,Shero ST,Smith SC,Watson K,Wilson PW;American College of Cardiology/American Heart Association Task Force on Practice Guidelines.2013ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol 2014;63:2889-2934[PMID:[[24239923 DOI:10.1016/j.jacc.2013.11.002]
20 Jellinger PS,Handelsman Y,Rosenblit PD,Bloomgarden ZT,Fonseca VA,Garber AJ,Grunberger G,Guerin CK,Bell DSH,Mechanick JI,Pessah-Pollack R,Wyne K,Smith D,Brinton EA,Fazio S,Davidson M.American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease.Endocr Pract 2017;23:1-87[PMID:[[28437620 DOI:10.4158/EP171764.APPGL]
21 American Diabetes Association.15.Diabetes Care in the Hospital:Standards of Medical Care in Diabetes-2019.Diabetes Care 2019;42:S173-S181[PMID:[[30559241 DOI:10.2337/dc19-S016]
22 Grundy SM,Stone NJ,Bailey AL,Beam C,Birtcher KK,Blumenthal RS,Braun LT,de Ferranti S,Faiella-Tommasino J,Forman DE,Goldberg R,Heidenreich PA,Hlatky MA,Jones DW,Lloyd-Jones D,Lopez-Pajares N,Ndumele CE,Orringer CE,Peralta CA,Saseen JJ,Smith SC,Sperling L,Virani SS,Yeboah J.2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNAGuideline on the Management of Blood Cholesterol.Circulation 2018;CIR0000000000000625[PMID:[[30586774 DOI:10.1161/CIR.0000000000000625]
23 Jialal I,Vikram N.Nutrition therapy for diabetes:Implications for decreasing cardiovascular complications.J Diabetes Complications 2017;31:1477-1480[PMID:[[28830659 DOI:10.1016/j.jdiacomp.2017.07.008]
24 Wu L,Piotrowski K,Rau T,Waldmann E,Broedl UC,Demmelmair H,Koletzko B,Stark RG,Nagel JM,Mantzoros CS,Parhofer KG.Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects:a randomized controlled cross-over clinical trial.Metabolism 2014;63:382-391[PMID:[[24360749 DOI:10.1016/j.metabol.2013.11.005]
25 Bao Y,Han J,Hu FB,Giovannucci EL,Stampfer MJ,Willett WC,Fuchs CS.Association of nut consumption with total and cause-specific mortality.N Engl J Med 2013;369:2001-2011[PMID:[[24256379 DOI:10.1056/NEJMoa1307352]
26 Klein S,Sheard NF,Pi-Sunyer X,Daly A,Wylie-Rosett J,Kulkarni K,Clark NG;American Diabetes Association;North American Association for the Study of Obesity;American Society for Clinical Nutrition.Weight management through lifestyle modification for the prevention and management of type 2diabetes:rationale and strategies:a statement of the American Diabetes Association,the North American Association for the Study of Obesity,and the American Society for Clinical Nutrition.Diabetes Care2004;27:2067-2073[PMID:[[15277443]
27 Wing RR,Lang W,Wadden TA,Safford M,Knowler WC,Bertoni AG,Hill JO,Brancati FL,Peters A,Wagenknecht L;Look AHEAD Research Group.Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes.Diabetes Care 2011;34:1481-1486[PMID:[[21593294 DOI:10.2337/dc10-2415]
28 Look AHEAD Research Group.Wing RR,Bolin P,Brancati FL,Bray GA,Clark JM,Coday M,Crow RS,Curtis JM,Egan CM,Espeland MA,Evans M,Foreyt JP,Ghazarian S,Gregg EW,Harrison B,Hazuda HP,Hill JO,Horton ES,Hubbard VS,Jakicic JM,Jeffery RW,Johnson KC,Kahn SE,Kitabchi AE,Knowler WC,Lewis CE,Maschak-Carey BJ,Montez MG,Murillo A,Nathan DM,Patricio J,Peters A,Pi-Sunyer X,Pownall H,Reboussin D,Regensteiner JG,Rickman AD,Ryan DH,Safford M,Wadden TA,Wagenknecht LE,West DS,Williamson DF,Yanovski SZ.Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.N Engl J Med 2013;369:145-154[PMID:[[23796131 DOI:10.1056/NEJMoa1212914]
29 Stancu C,Sima A.Statins:mechanism of action and effects.J Cell Mol Med 2001;5:378-387[PMID:[[12067471]
30 Arrigoni E,Del Re M,Fidilio L,Fogli S,Danesi R,Di Paolo A.Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Int J Mol Sci 2017;18[PMID:[[28067828 DOI:10.3390/ijms18010104]
31 Devaraj S,Rogers J,Jialal I.Statins and biomarkers of inflammation.Curr Atheroscler Rep 2007;9:33-41[PMID:[[17169243]
32 Collins R,Armitage J,Parish S,Sleigh P,Peto R;Heart Protection Study Collaborative Group.MRC/BHFHeart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes:a randomised placebo-controlled trial.Lancet 2003;361:2005-2016[PMID:[[12814710]
33 Neil HA,DeMicco DA,Luo D,Betteridge DJ,Colhoun HM,Durrington PN,Livingstone SJ,Fuller JH,Hitman GA;CARDS Study Investigators.Analysis of efficacy and safety in patients aged 65-75 years at randomization:Collaborative Atorvastatin Diabetes Study(CARDS).Diabetes Care 2006;29:2378-2384[PMID:[[17065671]
34 Diabetes Canada Clinical Practice Guidelines Expert Committee;Mancini GBJ,Hegele RA,Leiter LA.Dyslipidemia.Can J Diabetes 2018;42 Suppl 1:S178-S185[PMID:[[29650093 DOI:10.1016/j/jcjd.2017.10.019]
35 Cholesterol Treatment Trialists'(CTT)Collaborators;Kearney PM,Blackwell L,Collins R,Keech A,Simes J,Peto R,Armitage J,Baigent C.Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins:a meta-analysis.Lancet 2008;371:117-125[PMID:[[18191683 DOI:10.1016/S0140-6736(08)60104-X]
36 Thompson PD,Panza G,Zaleski A,Taylor B.Statin-Associated Side Effects.J Am Coll Cardiol 2016;67:2395-2410[PMID:[[27199064 DOI:10.1016/j.jacc.2016.02.071]
37 Ridker PM,Danielson E,Fonseca FA,Genest J,Gotto AM,Kastelein JJ,Koenig W,Libby P,Lorenzatti AJ,MacFadyen JG,Nordestgaard BG,Shepherd J,Willerson JT,Glynn RJ;JUPITER Study Group.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med2008;359:2195-2207[PMID:[[18997196 DOI:10.1056/NEJMoa0807646]
38 Cannon CP,Blazing MA,Giugliano RP,McCagg A,White JA,Theroux P,Darius H,Lewis BS,Ophuis TO,Jukema JW,De Ferrari GM,Ruzyllo W,De Lucca P,Im K,Bohula EA,Reist C,Wiviott SD,Tershakovec AM,Musliner TA,Braunwald E,Califf RM;IMPROVE-IT Investigators.Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.N Engl J Med 2015;372:2387-2397[PMID:[[26039521 DOI:10.1056/NEJMoa1410489]
39 Liu CH,Chen TH,Lin MS,Hung MJ,Chung CM,Cherng WJ,Lee TH,Lin YS.Ezetimibe-Simvastatin Therapy Reduce Recurrent Ischemic Stroke Risks in Type 2 Diabetic Patients.J Clin Endocrinol Metab2016;101:2994-3001[PMID:[[27270238 DOI:10.1210/jc2016-1831]
40 Staels B,Auwerx J.Regulation of apo A-I gene expression by fibrates.Atherosclerosis 1998;137 Suppl:S19-S23[PMID:[[9694537]
41 Superko HR,Berneis KK,Williams PT,Rizzo M,Wood PD.Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.Am J Cardiol 2005;96:1266-1272[PMID:[[16253595 DOI:10.1016/JAMJCARD.2005.06.069]
42 Rubins HB,Robins SJ,Collins D,Fye CL,Anderson JW,Elam MB,Faas FH,Linares E,Schaefer EJ,Schectman G,Wilt TJ,Wittes J.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.N Engl J Med 1999;341:410-418[PMID:[[10438259 DOI:10.1056/NEJM199908053410604]
43 Keech A,Simes RJ,Barter P,Best J,Scott R,Taskinen MR,Forder P,Pillai A,Davis T,Glasziou P,Drury P,Kes?niemi YA,Sullivan D,Hunt D,Colman P,d'Emden M,Whiting M,Ehnholm C,Laakso M;FIELD study investigators.Effects of long-term fenofibrate therapy on cardiovascular events in 9795people with type 2 diabetes mellitus(the FIELD study):randomised controlled trial.Lancet 2005;366:1849-1861[PMID:[[16310551 DOI:10.1016/S0140-6736(05)67667-2]
44 ACCORD Study Group;Ginsberg HN,Elam MB,Lovato LC,Crouse JR 3rd,Leiter LA,Linz P,Friedewald WT,Buse JB,Gerstein HC,Probstfield J,Crouse RH,Ismail-Beigi F,Bigger JT,Goff DC Jr,Cushman WC,Simons-Morton DG,Byington RP.Effects of combination lipid therapy in type 2 diabetes mellitus.N Engl J Med 2010;362:1563-1574[PMID:[[20228404 DOI:10.1056/NEJMoa1001282]
45 Jialal I,Amess W,Kaur M.Management of hypertriglyceridemia in the diabetic patient.Curr Diab Rep2010;10:316-320[PMID:[[20532703 DOI:10.1007/s11892-010-0124-4]
46 HPS2-THRIVE Collaborative Group.Landray MJ,Haynes R,Hopewell JC,Parish S,Aung T,Tomson J,Wallendszus K,Craig M,Jiang L,Collins R,Armitage J.Effects of extended-release niacin with laropiprant in high-risk patients.N Engl J Med 2014;371:203-212[PMID:[[25014686 DOI:10.1056/NEJMoa1300955]
47 Orringer CE,Jacobson TA,Saseen JJ,Brown AS,Gotto AM,Ross JL,Underberg JA.Update on the use of PCSK9 inhibitors in adults:Recommendations from an Expert Panel of the National Lipid Association.J Clin Lipidol 2017;11:880-890[PMID:[[28532784 DOI:10.1016/j.jacl.2017.05.001]
48 Robinson JG,Farnier M,Krempf M,Bergeron J,Luc G,Averna M,Stroes ES,Langslet G,Raal FJ,El Shahawy M,Koren MJ,Lepor NE,Lorenzato C,Pordy R,Chaudhari U,Kastelein JJ;ODYSSEY LONGTERM Investigators.Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.NEngl J Med 2015;372:1489-1499[PMID:[[25773378 DOI:10.1056/NEJMoa1501031]
49 Schwartz GG,Steg PG,Szarek M,Bhatt DL,Bittner VA,Diaz R,Edelberg JM,Goodman SG,Hanotin C,Harrington RA,Jukema JW,Lecorps G,Mahaffey KW,Moryusef A,Pordy R,Quintero K,Roe MT,Sasiela WJ,Tamby JF,Tricoci P,White HD,Zeiher AM;ODYSSEY OUTCOMES Committees and Investigators.Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.N Engl J Med2018;379:2097-2107[PMID:[[30403574 DOI:10.1056/NEJMoa1801174]
50 Sabatine MS,Giugliano RP,Wiviott SD,Raal FJ,Blom DJ,Robinson J,Ballantyne CM,Somaratne R,Legg J,Wasserman SM,Scott R,Koren MJ,Stein EA;Open-Label Study of Long-Term Evaluation against LDL Cholesterol(OSLER)Investigators.Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.N Engl J Med 2015;372:1500-1509[PMID:[[25773607 DOI:10.1056/NEJ-Moa1500858]
51 Nicholls SJ,Puri R,Anderson T,Ballantyne CM,Cho L,Kastelein JJ,Koenig W,Somaratne R,Kassahun H,Yang J,Wasserman SM,Scott R,Ungi I,Podolec J,Ophuis AO,Cornel JH,Borgman M,Brennan DM,Nissen SE.Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients:The GLAGOV Randomized Clinical Trial.JAMA 2016;316:2373-2384[PMID:[[27846344 DOI:10.1001/jama.2016.16951]
52 Sabatine MS,Giugliano RP,Keech AC,Honarpour N,Wiviott SD,Murphy SA,Kuder JF,Wang H,Liu T,Wasserman SM,Sever PS,Pedersen TR;FOURIER Steering Committee and Investigators.Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.N Engl J Med 2017;376:1713-1722[PMID:[[28304224 DOI:10.1056/NEJMoa1615664]
53 Sabatine MS,Leiter LA,Wiviott SD,Giugliano RP,Deedwania P,De Ferrari GM,Murphy SA,Kuder JF,Gouni-Berthold I,Lewis BS,Handelsman Y,Pineda AL,Honarpour N,Keech AC,Sever PS,Pedersen TR.Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes:a prespecified analysis of the FOURIER randomised controlled trial.Lancet Diabetes Endocrinol 2017;5:941-950[PMID:[[28927706 DOI:10.1016/S2213-8587(17)30313-3]
54 Hlatky MA,Kazi DS.PCSK9 Inhibitors:Economics and Policy.J Am Coll Cardiol 2017;70:2677-2687[PMID:[[29169476 DOI:10.1016/j.jacc.2017.10.001]
55 The Lipid Research Clinics Coronary Primary Prevention Trial results.I.Reduction in incidence of coronary heart disease.JAMA 1984;251:351-364[PMID:[[6361299]
56 Jialal I,Abby SL,Misir S,Nagendran S.Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes:a pooled analysis.Metab Syndr Relat Disord 2009;7:255-258[PMID:[[19344229 DOI:10.1089/MET.2009.0007]
57 Oikawa S,Yokoyama M,Origasa H,Matsuzaki M,Matsuzawa Y,Saito Y,Ishikawa Y,Sasaki J,Hishida H,Itakura H,Kita T,Kitabatake A,Nakaya N,Sakata T,Shimada K,Shirato K;JELIS Investigators,Japan.Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism:Sub-analysis of the Japan EPA Lipid Intervention Study(JELIS).Atherosclerosis 2009;206:535-539[PMID:[[19447387 DOI:10.1016/j.atherosclerosis.2009.03.029]
58 ORIGIN Trial Investigators.Bosch J,Gerstein HC,Dagenais GR,Díaz R,Dyal L,Jung H,Maggiono AP,Probstfield J,Ramachandran A,Riddle MC,Rydén LE,Yusuf S.n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.N Engl J Med 2012;367:309-318[PMID:[[22686415 DOI:10.1056/NEJMoa1203859]
59 Bhatt DL,Steg PG,Miller M,Brinton EA,Jacobson TA,Ketchum SB,Doyle RT,Juliano RA,Jiao L,Granowitz C,Tardif JC,Ballantyne CM;REDUCE-IT Investigators.Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.N Engl J Med 2019;380:11-22[PMID:[[30415628 DOI:10.1056/NEJMoa1812792]
